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Conserved cis-elements bind a protein complex that regulates Drosophila
ras2/rop bidirectional expression
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Summary The Drosophila ras2 promoter region exhibits bidirectional activity, as has been demonstrated for
the human c-Ha-rasl and the mouse c-Ki-ras. Here we address a unique case of ras regulation, as Drosophila
ras2 provides the only example to date in which the flanking gene (rop) and its product have been isolated. A
linking mechanism of control suggests a mutual interaction between the two gene products. Our studies
indicate that the Drosophila ras2 promoter region shares with the human c-Ha-rasl promoter a CACCC box
and an AP-l-like sequence. A 14 bp promoter fragment which holds a CACCC element is demonstrated to
interact with a specific transcription factor (factor B). This CACCC promoter element represents a stretch of
imperfect palindrome. We present evidence that this factor can form a complex with another specific
DNA-binding protein (factor A). The binding sites (A + B) for these protein factors are essential for 95%
expression of both genes flanking the promoter (ras2 and rop). Region A consists of four overlapping
consensus sequences: a TATA-like element, a DSE-like motif (the core sequence of the serum response
element), a DRE octamer, which has been shown to play a role in cell proliferation, and a 5 bp direct repeat
representing the GATA consensus sequence. Factor A has a very weak affinity to the full promoter region, but
when complexed with factor B binding efficiency is enhanced. We also show that alterations of DNA-protein
binding specificities can be achieved by supplementing the growth media with different sera.
The ras superfamily consists of more than 60 genes encoding
small GTPases that can switch from an inactive (GDP-
bound) state to an active (GTP-bound) state (Hall, 1990).
Although the best-known members are the ras proto-
oncogenes (Barbacid, 1987), the precise function of Ras pro-
teins remain unclear, though the prevailing view is that they
act as transducers of mitogenic signals (Chardin, 1991; Egan
et al., 1993). Their involvement in cellular differentiation and
cellular proliferation has been reviewed elsewhere (Barbacid,
1987; Bar-sagi & Feramisco, 1985; Birchmeier et al., 1985;
Feramisco et al., 1984; Hagag et al., 1986; McCormick,
1989). ras oncogenes are the most frequent group of
oncogenes so far identified in human cancers (Barbacid,
1987; Bos, 1988). A very high proportion - up to 30% - of a
variety of human tumours, including carcinomas, mela-
nomas, seminomas, leukaemias, sarcomas and neuroblas-
tomas, contain activated ras oncogenes (Almoguera et al.,
1988; Barbacid, 1990; Bos et al., 1987; Bos, 1989; Downward,
1990; Forrester et al., 1987; Spandidos, 1987). ras genes can
acquire transforming properties by qualitative and quan-
titative mechanisms (Alitalo, 1984; Chang et al., 1982;
Fasano et al., 1986). Mostly they owe their transforming
properties to single point mutations within their coding
region (Reddy et al., 1982; Tabin et al., 1982; Taparowsky et
al., 1982). However, in some cases, alteration of the
regulatory sequences of the gene may also induce its transfor-
ming activity as uncontrolled expression of such gene prod-
ucts could be expected to alter the fate and growth potential
of cells (Theillet et al., 1986).
Increasingly, evidence suggests that 10- to 100-fold
amplification of non-mutated ras genes can induce certain
manifestations of the malignant phenotype (Chang et al.,
1982). In several significant tumour types [breast (Hand et
al., 1984), colon (Gallick et al., 1985), gastric (Bos et al.,
1986), glial (Blin et al., 1987), lung and bladder cancers
(De-Biasi et al., 1989)] elevated levels of normal Ras protein
may well be crucial to tumorigenesis (Tanaka et al., 1986). It
has also been shown that high levels of ras product can lead
to transformation of certain recipient cell types (Chang et al.,
1982). It seems, therefore, that a combination of qualitative
and quantitative alterations within ras genes is capable of
inducing a more complete spectrum of neoplastic phenotypes.
Ras and Ras-related proteins have been highly conserved
in diverse living systems, and share similar structural and
biochemical properties (Barbacid, 1987; Chardin, 1988;
Dhar et al., 1984; Neuman-Silberberg et al., 1984; Reymond
et al., 1984). In Drosophila melanogaster, cellular genes
related to several viral oncogenes have been detected (Liven
et al., 1985; Shilo, 1987, Wadsworth et al., 1985). Three ras
genes have been isolated and termed rasi, ras2 and ras3.
These genes have been mapped to loci 85D, 64B and 62B
respectively, on the polytene chromosomes of larval salivary
glands (Neuman-Silberberg et al., 1984). They share on
average 80% similarity with vertebrate ras p21 proteins at
their N-terminus (Brock, 1987; Mozer et al., 1985; Neuman-
Silberberg et al., 1984). Structural homologies between the
Drosophila and vertebrate Ras proteins were demonstrated
by precipitating 21 kDa and 27-28 kDa proteins from
Drosophila cell extract using monoclonal antibodies raised
against the v-Ha-ras p21 protein (Papageorge et al., 1984). At
the functional level, it has previously been shown that ras
chimeric genes derived from Drosophila can promote neoplas-
tic transformation of mammalian cells (Schejter & Shilo,
1985). Recently, results show that Ras3 disrupts normal cell
fate specification in the photoreceptor cells in the Drosophila
developing eye (Hariharan et al., 1991), while Ras 1 has been
shown to participate in the transmission of signals involved
with this process (Rubin, 1991). The analogues in the mam-
malian system, rapl/Krev (ras3 homologues), have been
shown to suppress the transforming activity of the human
Ki-ras oncogene (Kitayama et al., 1989).
The Drosophila ras2 proto-oncogene is regulated by a
bidirectional promoter, as are the human c-Ha-rasl and the
mouse c-Ki-ras genes (Hoffman et al., 1987; Spandidos &
Riggio, 1986), but in the last two cases no specific opposite
transcribing gene has yet been identified. A distinct transcrip-
tion unit, which was termed rop (for ras opposite), has been
located only 94 bases upstream of the Drosophila ras2 gene,
and it seems that the ras2/rop promoter is one of the shortest
bidirectional promoters identified so far (Cohen et al., 1988).
Studies of the spatial distribution of the mRNA transcribed
from the two genes during development produced almost
identical patterns. Both genes are transcribed -in oocytes,
while in early embryos mRNA distribution is localised
mostly in the peripheral nervous system (Lev et al., 1985;
Segal & Shilo, 1986; Salzberg et al., 1993). Analysis of the
rop product revealed a 68 kDa non-nuclear protein situated
in both the membranous and the cytosolic subfractions (Salz-
berg et al., 1993).
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Precise characterisation of the entire transcriptional
mechanism controlling the expression of both genes may be
one approach to determine whether the rop gene product can
interact with the Ras protein in any way during signal trans-
duction. Identification of the DNA elements and protein
factors regulating the genes would provide some insight into
the various signals which might select for the induction of
one gene and others capable of inducing/repressing the simul-
taneous expression of both genes. Furthermore, a com-
parison of the conserved cis elements regulating the human
ras genes and the Drosophila ras2 gene should facilitate
detailed understanding of how specific factors can modulate
ras overexpression, and hence tumorigenesis.
In this paper we show that the ras2/rop bidirectional pro-
moter supports the transcription of both genes. This is prob-
ably achieved by one unitary complex and not by two
separate transcription complexes regulating each gene.
Mobility-shift assays indicate the binding of a single major
protein complex to the ras2lrop promoter. Evidence for the
interaction of two different factors (components of this main
protein complex), with a CACCC box-containing region and
another promoter fragment, which carries different overlap-
ping motifs, has been obtained by competition experiments,
partial purification of nuclear extract and DNAse I footprin-
ting analysis. The regions demarcated by these sequence
classes have been found necessary for maximal transcription
in both directions. In addition, it appears that by supplemen-
ting the cells with different serum components DNA-binding
specificity can be altered.
Materials and methods
Plasmid constructions
The Drosophila ras2 promoter and part of the downstream
non-translated region were linked to the bacterial chloram-
phenicol acetyl transferase (CAT) gene in the promoterless
vector p106 (a derivative of pSVOCAT; Gorman et al.,
1982). The same was done for the rop gene flanking the other
side of the promoter. The two constructs have been named
pRAS-CAT and pROP-CAT respectively. By introducing
progressive deletions into sequences upstream of the ras2 or
the rop transcription start sites, the following plasmids
were constructed: pRASO-CAT, pRAS1-CAT, pRAS2-CAT,
pRAS9-CAT, pRASl 1-CAT, pROPl-CAT, pROP4-CAT,
pROP5-CAT, pROP6-CAT, pROP7-CAT and pROP8-CAT.
The precise sites ofdeletions as determined by sequencing are
illustrated in Figure 6.
Oligonucleotides
The oligonucleotides (oligos) containing the different consen-
sus DNA-binding sequences or promoter elements were
chemically synthesised. Double-stranded oligos were used as
competitors and probes in the gel retardation assays. The
sequences of the sense strand of the oligos used were: RR1
(for right repeat of fragment I), 5'-CGCCCGTCTCAGTGC-
GAGT-3'; FRI (for fragment I), 5'-CGATCTAGCAGAGA-
CGCGCACCCGTCTCAGTGCGAGAGATCTG-3'; Fim (for
fragment I mutant), 5'-CGATCTAGCAGAGACGCGCAC-
TTGTCTC AGTGCGAGAGATCTG-3'; FR2 (for fragment
II), 5'-CGATCGTCTCAGTGCGAGTGTGGATTT CTCA-
GTTAACCGAGAA-3'; AP-1 (for AP-1 consensus sequence),
5'-CGATGAGTCAGATGAGTCAGT-3'; AP-Im (for AP-1
mutant), 5'-CGATGAGGTAGATGAGGTAGT-3'; TAT (for
TATA-like promoter sequence), 5'-CTAGGATATCGATAT-
TACTGTCTA-3'; and control sequence, 5'-AAGGCTACA-
CTGTTAATTTT-3'.
DNA transfection
Plasmids used for transfection were purified through a
caesium chloride gradient (Maniatis et al., 1989). For trans-
fection, 3 Zg of plasmid DNA was transfected into
Drosophila Schneider 2 (S2) cells (Schneider, 1972) by the
standard calcium phosphate procedure described by Quinones
et al. (1989). After 48 h in medium containing 10% fetal calf
serum (FCS, Highveld Biological) or fetal bovine serum
(FBS, Delta Bioproducts), the cells were harvested as des-
cribed by Gorman et al. (1982).
CAT assay
CAT activity was measured by assaying percentage incor-
poration of ['4C]acetyl coenzyme A (CoA) into chloram-
phenicol by the one-vial assay as described by Sleigh (1986).
All assays were performed in the linear range and equal
amounts ofprotein were used for each sample. Each plasmid,
from at least two different plasmid preparations, was tested
3-5 times. The copy number of transfected plasmids was
normalised by slot-blot hybridisation. Although we observed
that the magnitude of induction may vary from one batch of
cells to the next, the relative activities of each of the con-
structs remained constant.
Fractionation ofthe S2 nuclear extract
The Drosophila nuclear extract was prepared from logarith-
mically growing S2 cells essentially as described by Dignam
et al. (1983). The buffer used in all chromatographic steps
was buffer C (20 mM HEPES pH 7.9, 20 mm potassium
chloride, 1.5 mM magnesium chloride, 25% glycerol, 0.2 mM
EDTA, 1 mM DTT and 0.5 mM phenylmethylsulphonyl
fluoride). Heparin-agarose was purchased from Bio-Rad and
phosphocellulose was kindly provided by V. Mizrahi,
SAIMR. Typically, 5 mg of S2 nuclear extract was loaded on
3 ml heparin-agarose or phosphocellulose columns equili-
brated with buffer C, followed by elution with a sodium
chloride gradient (100-1,000 mM). Fractions were collected,
concentrated and dialysed against buffer C. Small aliquots of
all protein fractions were frozen in liquid nitrogen and stored
at - 70°C.
Bandmobility-shift assays
Gel retardation assays (Xiao et al., 1987) were performed
using 20jil reactions containing nuclear extract or chromato-
graphic fractions with 0.05-2 ytg ofpoly(dI-dC) (Sigma) and
0.8 ng of 32P-labelled DNA probes (approximately 30,000
counts per min, prepared using the Klenow fragment of
DNA polymerase I or polynucleotide kinase). The reactions
containing buffer C were incubated in the presence or
absence of a 10-, 20- or 40-fold molar excess of unlabelled
DNA competitors as described in the text. The unbound free
probes were resolved from the DNA-protein complexes by
electrophoresis through a 5-6% (29:1) non-denaturing
acrylamide gel in a buffer containing 45 mM Tris base, 45 mM
boric acid and 1 mM EDTA (pH 8.5) (Ryan et al., 1989). The
gels were then dried and exposed to Fuji X-ray film at room
temperature for approximately 24 h.
DNAse Ifootprinting
DNAse I protection assays were performed according to
Davidson et al. (1986) using the heparin-agarose column
fractions. The probe used was a 320 bp labelled fragment
containing the entire ras2/rop promoter and flanking regions.
Digestion with DNAse I (31gml-') was performed at 20°C
for 90s. The G+ A reaction was done as described by
Maxam and Gilbert (1980).
Results
One main protein complex binds the ras2/rop bidirectional
promoter
To identify the nuclear protein complexes regulating the
bidirectional expression of the ras2/rop constructs, we deter-266 K. LIGHTFOOT et al.
mined the ability of several promoter fragments to bind
transcription factors using gel-shift experiments and DNAse I
protection assays. Nuclear extracts were obtained from
Schneider 2 tissue culture cells (S2) and 12h embryos, in
which the promoter is similarly active in both directions.
Labelled restriction fragments from the promoter region were
incubated with nuclear extracts in the presence ofpoly(dI-dC)
to prevent 'non-specific' protein-DNA interactions. The re-
sulting complexes were separated by electrophoresis (Figure
1). Incubation of the entire promoter region with Drosophila
embryo nuclear extract (unpublished data), or S2 cell nuclear
extract, generated a primary retarded complex of relatively
high molecular weight, hereafter referred to as 'complex M'
(Figure la). Similarly, probing with a 59 nt sequence
upstream of the ras2 cap site identified the same retarded
complex M (Figure lb). An additional feature of these
determinations was the appearance, in certain of the nuclear
extracts, of two other factors with lower molecular weight
(see Figure 2a, lanes 1-4). For future reference these two
factors are denoted 'A' and 'B'. Recent experiments involv-
ing further purification of the factors A and B have shown
that together they occupy the same sites as complex M
within the ras2/rop bidirectional promoter (see below and
unpublished data). It would appear, therefore, that complex
M functions as a unit consisting of a number of constituent
factors.
Determination ofspecific protein binding sites
To identify the sequence specificity of the binding activity,
heparin-Ultragel fractions were subjected to DNAse I foot-
printing experiments. Double-stranded DNA containing the
ras2/rop promoter region was end labelled with 32P at posi-
tion -117 and used as the probe (see Figure 7). Following
incubation with the various fractions the probe DNA was
subjected to partial cleavage with pancreatic DNAse I. Reac-
tion with increasing amounts of the H.3 (300 mM) fraction
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Figure 1 In vitro protein-binding assay profile. Gel mobility-shift
assays were performed using 8-15 pg of Drosophila S2 cell
nuclear extract and I04c.p.m. of the probes listed below. Pro-
ducts were analysed by electrophoresis in a 6% polyacrylamide
gel. Probes: a, 123 bp fragment (-117 to 6); b, 59 bp fragment
(- 58 to 1); a and b, 2 jig of poly(dI-dC) was added to the
reaction. The main complex, complex M, is blocked by the
following plasmid vectors: a, pRAS 11-CAT; b, pRAS9-CAT; c,
pRASO-CAT; d, pROP4-CAT; and e, p106 (promoterless vector).
The assays contained I tLg of competitor DNA plasmid. F
represents free probe.
Figure 2 a, Dissociation of the main protein complex M into its
component subunits. DNA-binding assays were performed with
the following probes: the entire promoter region (lanes 1-4);
fragment I - 43 to - 11 (lane 5); TAT oligomer - 58 to - 39
(lane 6). Only A, B and M DNA-protein complexes are seen to
bind specific promoter sequences. Nuclear extract (NE) was
obtained from 12 h Drosophila embryos (lane 1) and S2 cells
supplemented with either FCS or FBS (lanes 2, 5 and 6). Only
the smaller DNA-protein complexes are apparent in this embryo
extract. Other preparations (not shown) demonstrated the
presence of the main protein complex - M. In some preparations
in which the NE was purified by heparin-agarose chromato-
graphy (lanes 3 and 4) the lower DNA-protein complexes, A
and B, were observed. This strongly suggests an association of
the smaller subunits, A and B, to form the major protein complex
M. Reaction conditions were as described in Materials and
methods. b, Gel mobility-shift assays were performed as for a but
with a 14 bp promoter fragment (- 25 to
-11) as the probe.
Products were analysed by electrophoresis in a 6% polyac-
rylamide gel. Assays were performed with varying concentrations
of poly(dI-dC): 0.05 iLg, 0.1 tLg, 0.2 fig and 0.5 pg in lanes 1-4
respectively. Lanes 5-8 contain the following oligomers as com-
petitors (1 pmol): lane 5, - 43 to -11; lane 6, - 25 to 15; lane 7,
- 43 to
-11, single strand; lane 8, control sequence (see
Materials and methods). Note the presence of the specific
DNA-protein complex B. n.s. = non-specific binding.
b
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(Figure 3a and b) revealed a distinct region of protection on
both strands (located between nucleotides - 73 and - 41)
identified as region A. Surprisingly, by replacing the medium
supplemented with FCS with medium containing FBS, pro-
tection of adjacent sequence motif - 41 to - 19 representing
the right central promoter region, that is region B, was
revealed (Figure 3d). As is indicated, DNAse I protection of
region B was inhibited exclusively by fragment I, while the
AP-1 consensus sequence site could not abolish complex
formation (Figure 4d). These DNAse I protected regions are
specific, behaving in a dose-dependent manner when sub-
jected to competition assays (Figure 3c). A remarkable dis-
covery is that inducing the cells with different sera confers
different DNA-binding specificites dependent on the type of
serum used. As the sera were purchased from different
sources we are presently unsure of the specific components
affecting the observed alteration in DNA-binding affinity.
Two proteinfactors interact specifically with regions A and B
Since DNAse I footprinting experiments showed that two
regions within the ras2/rop bidirectional promoter are
specifically protected, it was necessary to confirm that partic-
ular transcription factors interact exclusively with these
regulatory regions. Using gel shift experiments, three
different DNA-protein complexes were identified when a
33 bp oligomer fragment 1 (FRI, which overlaps region B)
was included as the probe in the reaction (Figure 2a, lane 5).
a b
The three were a double-stranded specific binding protein B
and two non-specific single-stranded binding proteins. These
results were confirmed using a second probe, RR1, consisting
of a 14 bp segment of FRI (Figure 2b). The smaller
DNA-protein complex, complex B, behaves like a typical
double-strand-specific binding protein as addition of 10- to
40-fold excess of identical unlabelled oligomers successfully
competes for the formation of this protein complex.
Making use of a 19 bp fragment overlapping region A
(- 58 to - 39, Figure 7), referred to as the TAT oligomer,
an additional three distinct factors were identified: a small
protein-DNA complex, complex A, which can only be
inhibited efficiently with the double-stranded TAT oligomer,
and two distinct but larger protein factors that bind non-
specifically to single-stranded DNA (Figure 2a, lane 6, and
unpublished data).
Therefore, making use primarily ofthe two oligomers TAT
and FRI we provide strong evidence for the binding of two
specific factors, A and B, to two adjacent sites in the central
region of the promoter.
Partialpurification ofthe trans-bindingfactors
The major protein complex M was partially purified by
chromatography on heparin-Ultragel or phosphocellulose
columns and the various fractions eluted used in mobility-
shift assays (see Figure 4). It is important to note that all
reactions employed equal amounts of protein. Using the
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Figure 3 DNAse I protection assay of the ras2/rop promoter. Using an end-labelled 320 bp fragment encompassing the promoter
region one region was apparent corresponding to region A: a, one of the DNA strands; b, the opposite DNA strand (see Figure 7
for the position of this region within the promoter). A 200 ng aliquot of poly(dI-dC) was added to the binding reactions. The salt
concentration of the various heparin-agarose fractions is indicated. Circle diameter represents the amount of extract added, i.e.
1 ytg or 2fig. Squares represent the amount of unlabelled fragment I (- 43 to -11) used as competitor, i.e. I pmol, 2 pmol and
5 pmol. c, two unlabelled competitors added along with the same probe as in b: = -117 to 6 and v = non-specific sequence from
p106 vector. The amount of competitor DNA is illustrated by black dots of increasing size, i.e. 0.5 pmol, 2.5 pmol, 5 pmol and
25 pmol. As for a and b, nuclear proteins were extracted from FCS-treated cells. d, 0.3 M sodium chloride fractions incubated with
various unlabelled fragments and the same probe as in a. In this case NE was prepared from FBS-treated cells. Using
heparin-agarose column fractions only one protected region was apparent corresponding to region B (see Figure 7). Competitors
used: a = fragment I (- 43 to -11); b = fragment I mutant; c = fragment II (- 25 to 15); d = AP-1 consensus sequence; e = AP-1
mutant. Competitors were added at the following concentrations: one dot, 0.05 pmol; two dots, 0.1 pmol; three dots, 2 pmol. The
nucleotide sequence was determined by the Maxam and Gilbert technique. Areas of protection are indicated by boxes A and B.268 K. LIGHTFOOT et al.
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Figure 4 DNA-binding assays of heparin-agarose gradient frac-
tions using end-labelled right repeat of fragment I-A fr.I (- 25
to -11). Binding reaction mixtures (12 jLI) include 0.05 jig poly-
(dI-dC), 104 c.p.m. labelled oligomer and 1 gig heparin-agarose
samples. b, longer exposure of a. Lane c = flow through fraction,
various fractions of 0.1 M-10 M sodium chloride. Competitor
oligomers: a = fragment I (- 43 to - 11); b = single-stranded
fragment I; c = single-stranded fragment II (- 25 to 15). c, Dimer
formation. Similar gel retardation experiment. Salt concentration
of fractions is indicated. s.s., non-specific binding to single-
stranded DNA; d.s. or DS, specific binding of factor B to the
probe. NE, nuclear extract from Drosophila Schneider 2 cells.
entire labelled promoter region as a probe, the majority of
complex M was eluted in the 300 mM sodium chloride frac-
tion of the type of column used (results not shown). This
represented an approximate 40-fold purification with respect
to the crude nuclear cell extract. Gel retardation assays
identified a number of factors using fractions from the
heparin-Ultragel column and a 32P-labelled RRI fragment
corresponding to region B. The 400 mM sodium chloride
fraction primarily contained the relatively low molecular
weight factor described as B above. The 200 mM sodium
chloride fraction did not show any specific binding activity
despite the presence of a higher molecular weight complex.
The 300mM sodium chloride eluate, however, showed the
presence of both the low molecular weight double-stranded
specific factor B and the larger protein-DNA complex with
a higher molecular weight, probably corresponding to com-
plex M above (Figure 4a and b). Interestingly, combining
aliquots of the 200 mM and 400 mM sodium chloride frac-
tions resulted in the enhancement of the larger complex M
with the concomitant reduction in the intensity of complex B
(Figure 4c).
Taken together, these results suggest the formation of a
heterodimer through the direct interaction between factor B
and another protein factor not capable of interacting directly
with RRI. This latter factor, factor A, is present in the
200mM and 30011M samples and contributes to the forma-
tion of the larger complex M seen when either RR1 or the
entire promoter region is used as a probe (unpublished data).
Moreover, the complexes were sequence specific since they
are greatly reduced when equivalent unlabelled promoter
elements were added to the reaction (see Figure 4b for
example).
Serum specificity
To investigate whether protein-DNA binding properties
could be altered by changing serum conditions only, nuclear
extracts from cells supplemented with either FBS or FCS
were examined by gel mobility-shift experiments. A series of
deletions of the ras2/rop promoter used as competitors
identified two regions as being necessary for binding to
occur. Employing nuclear extracts from S2 cells induced with
FBS, or 12 h embryos, the right central region of the pro-
moter (- 32 to 1 overlapping region B, Figure 7) was shown
to bind the large protein complex, complex M. This is illus-
trated in Figure Sa and b, in which the three different com-
petitors G, H and I (representing a 63 bp fragment - 95 to
- 32) were unable to block complex formation. Furthermore,
CAT expression assays showed that the same region of DNA
gave the highest levels of promoter activity in transfected
FBS-supplemented cells and injected embryos (see below).
Cells exposed to FCS, however, showed that the same
large protein complex M binds the left central region of the
promoter - 70 to - 47 (Figure 5c). This is evident from the
combined results of competitors C and G, which account for
the regions between - 95 and - 70 and also between - 47
and 1, which were unable to block the formation of complex
M.
The results presented here indicate the presence of one
main protein complex, complex M, capable of interacting
with the central promoter region and thus regulating the
expression of both genes. Corresponding to the DNAse I
protection analysis, alteration of serum components
presumably modifies the relative DNA-binding specificity of
the two constituent proteins of this complex. This could be
the result of subtle differences in any number of factors
constituting the two sera.
ras2/rop promoter activity
A series of constructs of the Drosophila ras2/rop promoter
with specific deletions was tested for possible regulatory roles
in the presence of either FBS or FCS. The fortuitous
differences in binding activity between FBS- and FCS-
supplemented cells proved to be a useful assay permitting us
to select for two distinct DNA-protein binding events. Each
reporter plasmid contained part of the ras2/rop promoter as
well as the 5' non-translated regions of ras2 or rop, joined to
the Escherichia coli chloramphenicol acetyl transferase (CAT)
gene (Figure 6, see Materials and methods for details). The
promoterless plasmid p106 (see Materials and methods) was
introduced as the control. All plasmids were transfected into
Drosophila S2 cells grown in the presence of either 10% FCS
or 10% FBS. CAT activity was assayed 48 h later. It is
important to note that DNA concentration was normalised
after transfection using slot-blot analysis.
The compositions of the various deletions and their
relative promoter activities in the transient expression assay
are shown in Figure 6a and b (ras2-CAT and rop-CAT
respectively). The data obtained from cells supplemented
with FBS show that the region of the ras2/rop promoter that
stretches approximately from - 52 to - 15 is necessary for
maximal bidirectional promoter activity. Removal of the
region between - 95 and - 58 or between - 95 and - 47
(pRAS9-CAT and pRAS2-CAT) produced a 5% and 40%
decrease in ras2-CAT expression respectively. Further trunca-ras2/rop BIDIRECTIONAL EXPRESSION IN DROSOPHILA 269
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Figure 5 Identification of specific protein binding sites in the
ras2/rop promoter. Gel retardation was performed using 10fig of
Drosophila embryo nuclear extract or S2 cell extract with 2 jig of
poly(dI-dC) and the entire ras2/rop promoter region (- 117 to
6) as the probe. The sites of protein-DNA interactions were
determined using 1 tLg (one dot) and 2jig (two dots) of the
following promoter constructs as competitors: C, pRAS2-CAT;
D, pRAS9-CAT; E, pRASI1-CAT; F, pRAS-CAT; G, pROP4-
CAT; H, pROP5-CAT; I, pROP6-CAT; J, pROP8-CAT; K,
pROP-CAT. Dark square = no competitor added. M = main
complex. a and c, extracts derived from S2 cells induced with
FBS and FCS respectively. b, extracts derived from 12 h embryos.
Note the change in DNA-binding activity with the change in
serum supplementation.
tions of the promoter region (constructs pRASI-CAT, - 85
to - 24; and pRASO-CAT, - 74 to - 5) showed levels of
ras2-CAT expression below 10%. Deletion of the right region
of the promoter in the ROP-CAT set of plasmids (- 32 to
32, pROP6-CAT) resulted in 65% decrease in rop-CAT
expression. Further deletions of the central region (plasmids
pROP5-CAT, - 52 to 1; pROP4-CAT, - 70 to 1; and
pROPl-CAT, - 86 to - 15) led to drastically diminished
rop-CAT expression. Combined, these deletion data suggest
that approximately 32 bp (- 47 to - 15) are essential for
transcription efficiency of at least 60%, in both directions, in
the presence of FBS. Two features worth noting in the
nucleotide sequence in this region are (i) the presence of an
AP-l-like sequence and (ii) a perfect CACCC consensus
sequence in the centre of a hairpin structure (Figure 7).
Transfecting S2 cells, grown in the presence of FCS, with
these same constructs produced noticeably different results
(Figure 6a and b). Paralleling the above, pROPI-CAT and
pROP4-CAT, together accounting for the regions between
- 95 and - 70 and between - 15 and 32, contribute to not
more than 3% promoter activity. Fifty to sixty per cent of
ROP-CAT expression was achieved by introducing pROP6-
CAT (representing the region between - 95 and - 32), while
removal of a region between - 118 and - 47 (pRAS2-CAT)
resulted in a 60-70% decrease in RAS2-CAT expression. In
addition, results obtained with pRASO-CAT and pRASI-
CAT which extend from -118 to -74 and -24 to 1
demonstrate promoter activity of less than 5%. Together,
these data support the conclusion that in the presence of FCS
the promoter activity, although focused at the centre of the
bidirectional promoter as above (- 70 to - 15), is shifted
slightly upstream (graphically represented in Figure 6c). With
FBS as the supplement the region between - 47 and - 15
(see constructs pRAS1-CAT, pRAS2-CAT, pROP1-CAT and
pROP6-CAT) contributes to approximately 60% ofpromoter
activity. In contrast, this same region contributes not more
than 40% using nucelar extract of cells grown in FCS-
supplemented medium. Further, the region between - 70 and
- 32 (see constructs pRASO-CAT, pRAS2-CAT, pROP4-
CAT and pROP6-CAT) supports 50-60% of the bidirec-
tional expression in the presence of FCS, but only 30-40%
when FBS is added.
A point worth noting is that injecting Drosophila embryos
with the same constructs produced almost identical results as
those obtained with the FBS-supplemented cells (unpublished
data). It therefore appears that different serum conditions
can alter the specificity of DNA-protein binding interactions
and as a result affect gene regulation. As mentioned previ-
ously, the precise nature of the relative differences between
the two sera is not well understood, but preliminary results
indicate that differences in salt concentration may play a role
in this regard.
Closer examination of the left central region revealed
different overlapping sequence motifs, some of which exhib-
nit homology to known consensus elements, that is a TATA-
like element; a sequence which shares 85% homology with
the dyad symmetry element (CCArGG box - the core
sequence of the serum response element); DRE - an octamer
representing an element found upstream of two DNA
replication-related genes; and a 5bp GATA sequence
(GATAT/G) repeated seven times.
Discussion
Integrated into the functional network of oncoproteins must
be mechanisms for the mutual regulation of oncogene expres-
sion, since the dose and activity of each member of the
network need to be tightly controlled. Since none of the
cellular factors is constitutively active, there is always the
possibility that oncogenicity results from an altered response
to regulation.
In this article we have presented structural and functional
evidence suggesting that the two genes flanking the bidirec-
tional promoter (ras2 and rop) are regulated by a single
protein complex (complex M). Complex M exerts its
influence over the promoter via its interaction with the cen-
tral region, which falls primarily between positions - 73 and
- 19. Evidence is also presented for the presence of two
other distinct protein factors (A and B) which bind neigh-
bouring DNA elements, - 73 to - 41 and - 41 to - 19
respectively. It is suggested that the cooperative binding of
these two factors, probably leading to complex M formation,
accounts for maximum efficiency in the transcriptional
regulation of the ras2 and rop genes. This implies that,
although both elements are necessary for full expression,
tissue specificity can be achieved by inducing only a single
gene. Sharing of regulatory elements between two divergent
genes has been shown for the ol(IV) and a2(IV) collagen
genes. In this instance, both genes use the same bidirectional
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Figure 6 Deletion analysis of the bidirectional ras2/rop promoter. Schneider 2 cells, supplemented with FCS or FBS, were
transfected with deleted, a, ras2-CAT and, b, rop-CAT fusions and the relative CAT activity monitored. ras2 and rop transcription
start sites are identified as + and - 95 respectively. Arrows show the direction of transcription. The ras2-CAT and rop-CAT
fusions are schematically represented at the bottom of a and b respectively. Grey bars indicate sequences which are present within
each transfected clone. The effect of serum supplementation on relative promoter strength, as detected by the CAT assays, is
schematically represented in c. Two central promoter regions are necessary for obtaining more than 90% expression of both genes
in either FBS or FCS supplemented media, but different media contribute to changes in sequence-specific promoter activity.
promoter, which employs the identical enhancer within the
first intron of the xl(IV) gene for efficient transcriptional
activity (Burbelo et al., 1988). Separate transcriptional
mechanisms also occur, an example being the bidirectional
promoter of the his3 and petS6 genes in yeast. Among the
trans factors interacting with this promoter, the GCN4
activator can induce his3 expression but not pet56 expression
in the opposite direction (Struhl, 1987). In this context it
should be noted that several gene pairs regulated by bidirec-
tional promoters are ubiquitously expressed [the mouse
DHFR gene and small nuclear RNAs (Farnham et al., 1985);
the Drosophila tl and t2 genes (Swaroop et al., 1986); and
the mouse surf-1 and surf-2 genes (Williams & Fried, 1986)].
A possible regulatory interaction between the ras2 and rop
products has been proposed by Salzberg et al. (1993). The
expression patterns of these two genes is almost identical in a
given tissue. rop is simultaneously expressed with ras2 in
oocytes and the peripheral nervous system of Drosophila
embryos. rop (but not ras2) is also present in the embryonic
central nervous system. In the larva, ras and rop activity is
limited to specific sites within the ventral ganglion and the
brain hemispheres. In the adult, transcripts are found in the
legs, wings and specific nerve cells of the brain (Salzberg et
al., 1993). Taken together, these findings suggest a possible
interaction between the two gene products in both un-
differentiated proliferating cells and terminally differentiated
tissues.
Vertebrate ras promoters are generally GC rich, do not
contain the consensus sequences directing polymerase II
transcription such as the TATA box, but do contain a
number of GC boxes (Hall & Brown, 1985; Ishii et al.,
1985a; McGrath et al., 1984; Spandidos & Riggio, 1986).ras2/rop BIDIRECTIONAL EXPRESSION IN DROSOPHILA 271
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Figure 7 The nucleotide sequence of the ras2/rop promoter (with alterations by A. Slazberg and Z. Lev, personal communication).
+ 1 represents the ras2 transcription start site. Shaded and open triangles: transcription start sites determined by T4 polymerase
external primer extension and by RNAse protection respectively. Arrows indicate the direction of transcription: numbered
arrows = direct and inverted repeats with more than 80% similarity; large ellipses = direct and inverted insect cap box; open
circle = AP-l-like sequence; small ellipse = TATA-like sequence; small square = high homology to the core sequence of the SRE;
broken line = DRE motif; closed bar = pentamer repeat; open squares = protected regions by DNAse I; cruciform structure =
CACCC consensus sequence; black squares = fragment I and fragment II as indicated.
These features are very similar to those of the human EGF
receptor promoter (Ishii et al., 1985b) and to those of a
number of cellular housekeeping gene promoters [e.g. HMG
coenzyme A reductase (Osborne et al., 1985); mouse and
human DHFR (Farnham et al., 1985; Masters & Atgardi,
1985); human superoxide dismutase (Levanon, 1985)]. In the
human c-Ha-rasl promoter region, multiple elements are
required for transcriptional control. Among them are the
Spl-binding sites, a CCAAT box element and a CACCC box
element (also found in globin gene promoters), which are
necessary for maximal promoter activity (Lowndes et al.,
1989; Takahiro et al., 1990). The Drosophila ras2 promoter
region shares a conserved CACCC element with the human
c-Ha-rasl promoter. This motif lies in a stretch of imperfect
palindrome and has the potential to form cruciform struc-
tures containing mismatched base pairs. This is common to
many genes that harbour CREs in their promoter region and
are induced by cAMP (McMurray et al., 1991). In this
instance, it is possible that formation of cruciform structures
may be a general feature of certain classes of cis elements.
One of the components of the main protein complex des-
cribed here, factor B, has been found to interact with a
promoter region spanning the CACCC element. This element
has previously been shown to bind the general transcription
factor Spl (Yu et al., 1991). As Drosophila cells seem to lack
homologues of this binding protein (Santoro et al., 1988),
mutational analysis, competition experiments and affinity
purification of this binding factor will indicate which factor
can bind this element in Drosophila cells. Without knowledge
of the precise mechanisms of transcription initiation of
TATA-less promoters, it has been suggested that in these
promoters containing CACCC or Spl binding sites transcrip-
tion factors can substitute for TFIID function to initiate
transcription (Tamura & Katsuhiko, 1991).
The second component of the major complex, the A-region
binding factor (factor A), alone interacted very poorly with
the promoter region. However, by forming a heterodimer
with the B factor, binding efficiency to the A region is
enhanced. To date there are reports of many transcription
factors that bind to DNA as dimers of either homomeric or
heteromeric composition. It may be that heterodimers have
sequence specificities different from either of the individual
constituents (Hunter, 1991; Jones, 1990; Lewin, 1991).
The TATA-like sequence within region A may serve to
identify both the sense strand and the precise transcription
start point for the rop gene. Two DNA replication-related
genes, the proliferating cell nuclear antigen (PCNA) and the
Drosophila DNA polymerase, have been found to contain an
8 bp promoter element TATCGATA-DRE in their regula-
tory region (Yamaguchi et al., 1991). Strikingly, there is
complete homology (100%) between this regulatory element
and region A. If the DRE motif plays a role in the regulation
of ras2 expression it might be that DNA replication-related
genes are final targets of the ras signal pathway and hence
may all be regulated by a common mechanism.
An initiator element present at the ras2 transcription start
site, the cap box, has been found in approximately 60% of
all promoters (Bucher, 1990). This element has been shown
to be non-essential for promoter activity in certain cases
(Grosschedl & Birnstiel, 1980), but a prerequisite for trans-
cription of other genes (Arkhipova & Ilyin, 1991). The posi-
tional distribution of this element shows striking congruency
between vertebrate and non-vertebrate promoters. The
obvious candidates for binding to this weak cap signal are
RNA polymerase II and transcription factor TFIID (Naka-
jima, 1988). No protein binding was observed to the cap box
repeats in the vicinity of the ras2 transcription start site.
Furthermore no essential promoter activity could be
identified solely in the presence of this cap box element.
Of interest is the observation that altered DNA-protein
binding specificities can be achieved by supplementing the
growth media with different sera. Observations from different
systems have shown that hormone binding can induce a
conformational change in the oestrogen receptor, which leads
to an increased affinity for DNA (McGrogan et al., 1985;
Skafar & Notides, 1985), while HBV X protein can alter the
DNA-binding specificity of CREB and ATF-2 by pro-
tein-protein interactions (Maguire et al., 1991). The precise
effect of any given factor is determined by a variety of
elements, such as cell type, concentration of factor and the
duration of the stimulus, with the result that certain growth
factors may fulfil quite different functions under different
circumstances. Changing serum conditions might cause
modifications in enzymes that act upon such elements, which
in turn may influence the regulatory machinery. The above
demonstration of serum-specific changes might mean that
region A mediates transcriptional activation under certain
conditions through serum stimulation. It is well known that
serum induction of cell division requires ras protein and
possibly ras expression, based on the fact that the levels of
transcription of several other proto-oncogenes are increased
soon after serum addition (Gauthier-Rouviere et al., 1990;
Mulcahy et al., 1985). The ras protein may, therefore, repre-
sent a common element in the molecular cascade of events
initiated by numerous growth factors referred to as serum
components.
Since the ras genes are a ubiquitous gene family and likely
to play a fundamental role in normal cellular function based
on their high degree of conservation throughout eukaryotic
evolution, it is not unexpected that their regulatory mech-
anisms may have been conserved to some degree as well.
2
1 11
1.-. F---4 F-.-i272 K. LIGHTFOOT et al.
We are grateful to Professor Igor Dawid for providing the
Drosophila S2 cells, and to Professor Pierre Chambon and Professor
Dawid Botes for synthesising the oligomers. We thank Dr Zeev Lev
and co-workers for the use of the promoter deletion constructs and
Dr Yamaguchi for his useful comments. Thanks are also due to Dr
Zeev Lev and Professor Barry Fabian for the critical reading of the
manuscript. This work was supported by the South African Medical
Research council, the Foundation for Research and Development
and Griffin Cancer Trust.
References
ALITALO, K. (1984). Amplification of cellular oncogenes in cancer
cells. Med. Biol., 62, 304-317.
ALMOGUERA, C., SHIBATA, D., FORRESTER, K., MARTIN, J., ARN-
HEIM, N. & PERUCHO, M. (1988). Most human carcinomas of the
exocrine pancreas contain mutant c-K-ras genes. Cell, 53,
549-554.
ARKHIPOVA, I.R. & ILYIN, Y.V. (1991). Properties of promoter
regions of Mdgl Drosophila retrotransposon indicate that it
belongs to a specific class of promoters. EMBO J., 10,
1169-1177.
BARBACID, M. (1987). Ras genes. Annu. Rev. Biochem., 56, 779-827.
BARBACID, M. (1990). Ras oncogenes: their role in neoplasia. Eur. J.
Clin. Invest., 20, 225-235.
BAR-SAGI, D. & FERAMISCO, J.R. (1985). Microinjection of the ras
oncogene protein into PC12 cells induces morphological differ-
entiation. Cell, 42, 841-848.
BIRCHMEIER, C., BROEK, D. & WIGLER, M. (1985). RAS proteins
can induce miosis in Xenopus oocytes. Cell, 43, 615-621.
BLIN, N., MULLER-BRECHLIN, R., CARSTENS, C., MEESE, E. &
ZANG, K.D. (1987). Enhanced expression of 4 cellular oncogenes
in a human glioblastoma cell-line. Cancer Genet. Cytogenet., 25,
285-292.
BOS, J.L. (1988). The ras gene family and human carcinogenesis.
Mutat. Res., 195, 255-271.
BOS, J.L. (1989). Ras oncogenes in human cancer - a review. Cancer
Res., 49, 4682-4689.
BOS, J.L., VERLAAN-DE VRIES, M., MARSHALL, C.J., VEENEMAN,
G.H., VAN BOOM, J.H. & VAN DER EB, A.J. (1986). A human gastric
carcinoma contains a single mutated and an amplified normal
allele of the Ki-ras oncogene. Nucleic Acids Res., 14, 1209-1217.
BOS, J.L., FEARON, E.R., HAMILTON, S.R., VERLAAN-DE VRIES, M.,
VAN BOOM, J.H., VAN DER EB, A.J. & VOGELSTEIN, B. (1987).
Prevalence of ras gene-mutations in human colorectal cancers.
Nature, 327, 293-297.
BROCK, H.W. (1987). Sequence and genomic structure of ras
homologs Dmras85D and Dmras64B of Drosophila melanogaster.
Gene, 51, 129-137.
BUCHER, P. (1990). Weight matrix descriptions of 4 eukaryotic RNA
polymerase II promoter elements derived from 502 unrelated
promoter sequences. J. Mol. Biol., 212, 563-578.
BURBELO, P.D., MARTIN, G.R. & YAMADA, Y. (1988). 1(IV) and
2(IV) collagen genes are regulated by a bidirectional promoter
and a shared enhancer. Proc. Natl Acad. Sci. USA, 85,
9679-9682.
CHANG, E.H., FURTH, M.E., SCOLNICK, E.M. & LOWY, D.R. (1982).
Tumorigenic transformation of mammalian cells induced by a
normal human gene homologous to the oncogene of Harvey
Murine Sarcoma virus. Nature, 297, 479-483.
CHARDIN, P. (1988). The ras superfamily proteins. Biochimie, 70,
865-868.
CHARDIN, P. (1991). Small GTP-binding proteins of the ras family -
a conserved functional mechanism. Cancer Cells, 3, 117-126.
COHEN, N., SALZBERG, A. & LEV, Z. (1988). A bidirectional pro-
moter is regulating the Drosophila ras2 gene. Oncogene, 3,
137-142.
DAVIDSON, I., FROMENTAL, C., AUGEREAU, P., WILDEMAN, A.,
ZENKE, M. & CHAMBON, P. (1986). Cell-type specific protein
binding to the enhancer of simian virus 40 in nuclear extracts.
Nature, 323, 544-548.
DE-BIASI, F., DELSAL, G. & HAND, P.H. (1989). Evidence of enhance-
ment of the ras oncogene protein product p21 in a spectrum of
human tumors. Int. J. Cancer, 43, 431-435.
DHAR, R., NIGTU, A., KOLLER, R., DEFEO-JONES, D. & SCOLNICK,
E.M. (1984). Nucleotide sequence of two ras related-genes isolated
from the yeast Saccharomyces cerevisiae. Nucleic Acids Res., 12,
3611-3618.
DIGNAM, J.D., LEBOVITZ, R.M. & ROEDER, R.G. (1983). Accurate
transcription initiation by RNA polymerase II in a soluble ex-
tract from isolated mammalian nuclei. Nucleic Acids Res., 11,
1475-1489.
DOWNWARD, J. (1990). The ras superfamily of small GTP-binding
proteins. Trends Biol. Sci., 15, 469-472.
EGAN, S.E., GIDDINGS, B.W., BROOKS, M.W., BUDAY, L., SIZE-
LAND, A.M. & WEINBERG, R.A. (1993). Nature, 363, 45-51.
FARNHAM, P.J., ABRAMS, J.M. & SCHIMKE, R.T. (1985). Opposite-
strand RNAs from the 5' flanking region of the mouse Dihyd-
rofolate Reductase gene. Proc. Natl Acad. Sci. USA, 82,
3978-3982.
FASANO, O., ALDRICH, T., TAMANOI, F., TAPAROWSKY, E.,
FURTH, M. & WIGLER, M. (1986). Analysis of the transforming
potential of the human H-ras gene by random mutagenesis. Proc.
Natl Acad. Sci. USA, 81, 4008-4012.
FERAMISCO, J.R., GROSS, M., KAMATA, T., ROSENBERG, M. &
SWEET, R.W. (1984). Microinjection of the oncogene form of the
human H-ras (T24) protein results in rapid proliferation of quis-
cent cells. Cell, 38, 109-117.
FORRESTER, K., ALMOGUERA, C., HAN, K., GRIZZLE, W.E. &
PERUCHO, M. (1987). Detection of high-incidence of K-ras
oncogenes during human colon tumorigenesis. Nature, 327,
298-303.
GALLICK, G.E., KURZROCK, R., KLOETZER, W.S., ARLINGHAUS,
R.B. & GUTTERMAN, J.U. (1985). Expression of p2lras in fresh
primary and metastatic human colorectal tumors. Proc. Natl
Acad. Sci. USA, 82, 1795-1799.
GAUTHIER-ROUVIERE, C., FERNANDEZ, A. & LAMB, N.J.C. (1990).
Ras-induced c-fos expression and proliferation in living rat
fibroblasts involves c-kinase activation and the serum response
element pathway. EMBO J., 9, 171-180.
GORMAN, C.M., MERLINO, G.T., WILLINGHAM, M.C., PASTAN, I. &
HOWARD, B.H. (1982). Recombinant genomes which express
chloramphenicol acetyltransferase in mammalian cells. Mol. Cell.
Biol., 2, 1044-1051.
GROSSCHEDL, R. & BIRNSTIEL, M.L. (1980). Identification of
regulatory sequences in the prelude sequence of an H2A histone
gene by the study of specific deletion mutants in-vivo. Proc. Nail
Acad. Sci. USA, 77, 1432-1436.
HAGAG, N., HALEGONA, S. & VIOLA, M. (1986). Inhibition of
growth factor-induced differentiation of Pc12 cells by microinjec-
tion of antibody to Ras p21. Nature, 319, 680-682.
HALL, A. (1990). The cellular functions of small GTP binding pro-
teins. Science, 249, 635-640.
HALL, A. & BROWN, R. (1985). Human N-ras: cDNA cloning and
gene structure. Nucleic Acids Res., 13, 5255-5268.
HAND, P.H., THOR, A., WUNDERLICH, D., MAURANO, R., CARUSO,
A. & SCHLOM, J. (1984). Monoclonal antibodies of pre-defined
specificity detect activated ras gene expression in human mam-
mary and colon carcinomas. Proc. Natl Acad. Sci. USA, 81,
5227-5231.
HARIHARAN, I.K., CARTHEW, R.W. & RUBIN, G.M. (1991). The
Drosophila roughened mutation: activation of a rap homolog
disrupts eye development and interferes with cell determination.
Cell, 67, 717-722.
HOFFMAN, E.K., TRUSKO, S.P., FREEMAN, N. & GEORGE, D.L.
(1987). Structural and functional characterization of the promoter
region of the mouse c-K-ras gene. Mol. Cell. Biol., 7, 2592-2596.
HUNTER, T. (1991). Cooperation between oncogenes. Cell, 64,
249-270.
ISHII, S., MERLINO, G.T. & PASTAN, I. (1985a). Promoter region of
the human Harvey ras proto-oncogene: similarity to the EGF
receptor proto-oncogene promoter. Science, 230, 1378-1381.
ISHII, S., XU, Y.-H., STRATTON, R.H., ROE, B.A., MERLINO, G.T. &
PASTAN, I. (1985b). Characterization and sequence of the pro-
moter region of the human epidermal growth factor receptor
gene. Proc. Natl Acad. Sci. USA, 82, 4920-4924.
JONES, N. (1990). Transcriptional regulation by dimerization - 2
sides to an incestuous relationship. Cell, 61, 9-11.
KITAYAMA, H., SUGIMOTO, Y., MATSUZAKI, T., IKAWA, Y. &
NODA, M. (1989). A ras-related gene with transformation sup-
pressor activity. Cell, 56, 77-84.
LEV, Z., KIMCHIE, Z., HESSLE, R. & SEGEV, 0. (1985). Expression of
ras cellular oncogenes during development of Drosophila
melanogaster. Mol. Cell. Biol., 5, 1540-1542.ras2/rop BIDIRECTIONAL EXPRESSION IN DROSOPHILA 273
LEVANON, D., LIEMAN-HURWITS, J., DAFNI, N., WIGDERSON, M.,
SHERMAN, L., BERNSTEIN, Y., LAVER-RUDICH, Z., DANCIGER,
E., STEIN, 0. & GRONER, Y. (1985). Architecture and anatomy of
the chromosomal locus in human chromosome 21 encoding the
Cu/Zn superoxide dismutase. EMBO J., 4, 77-84.
LEWIN, B. (1991). Oncogenic conversion by regulatory changes in
transcription factors. Cell, 64, 303-312.
LIVEN, E., GLAZER, L., SEGAL, D., SCHLESSINGER, J. & SHILO, B.-Z.
(1985). The Drosophila EGF receptor gene homology: conserva-
tion of both hormone binding and kinase domains. Cell, 40,
599-607.
LOWNDES, N.F., PAUL, J., WU, J. & ALLAN, M. (1989). c-Ha-ras gene
bidirectional promoter expressed in-vitro location and regulation.
Mol. Cell. Biol., 9, 3758-3770.
MCCORMICK, F. (1989). Ras GTPase activating protein - signal
transmitter and signal terminator. Cell, 56, 5-8.
MCGRATH, J.P., CAPON, D.J., GOEDDEL, D.V. & LEVINSON, A.D.
(1984). Comparative biochemical properties of normal and
activated human ras p21 protein. Nature, 310, 644-649.
MCGROGAN, M., SIMONSEN, C.C., SMOUSE, O.T., FARNHAM, P.J. &
SCHIMKE, R.T. (1985). Heterogeneity at the estrogen receptor's
affinity for DNA by estradiol. J. Biol. Chem., 260, 2307-2314.
MCMURRAY, C.T., WILSON, W.D. & DOUGLASS, J.O. (1991). Hairpin
formation within the enhancer region of the human enkephalin
gene. Proc. Natl Acad. Sci. USA, 88, 666-670.
MAGUIRE, H.F., HOEFFLER, J.P. & SIDDIQUI, A. (1991). HBV
X-protein alters the DNA-binding specificity of Creb and ATF-2
by protein-protein interactions. Science, 252, 842-844.
MANIATIS, T., FRISCH, E. & SAMBROOK, J. (1989). Purification of
plasmid DNA. Molecular Cloning: A Laboratory Manual,
pp. 42-46. Cold Spring Harbor Laboratory Press: Cold Spring
Harbor, NY.
MASTERS, J.N. & ATTARDI, G. (1985). Human dihydrofolate reduc-
tase gene transcripts present in polysomal RNA map with their 5'
ends several hundred nucleotides upstream of the main mRNA
start site. Mol. Cell. Biol., 5, 493-500.
MAXAM, A.M. & GILBERT, W. (1980). Sequencing end-labeled DNA
with base-specific chemical cleavages. Methods Enzymol., 65,
499-560.
MOZER, B., MARLOR, R., PARKHURST, S. & CORCES, V. (1985).
Characterization and developmental expression of the Drosophila
ras oncogene. Mol. Cell. Biol., 5, 885-889.
MULCAHY, L.S., SMITH, M.R. & STACEY, D.W. (1985). Requirement
for ras proto-oncogene function during serum-stimulated growth
of NIH 3T3 cells. Nature, 313, 241-243.
NAKAJIMA, N., HORIKOSHIM, M. & ROEDER, R.G. (1988). Factors
involved in specific transcription by mammalian RNA poly-
merase II - purification, genetic specificity, and TATA-box pro-
moter interactions of TFIID. Mol. Cell. Biol., 8, 4028-4040.
NEUMAN-SILBERBERG, F.S., SCHEJTER, E., HOFFMANN, F.M. &
SHILO, B.-Z. (1984). The Drosophila ras oncogenes: structure and
nucleotide sequence. Cell, 37, 1027-1033.
OSBORNE, T.F., GOLDSTEIN, J.L. & BROWN, M.S. (1985). 5' end of
HMG CoA reductase gene contains sequences responsible for
cholesterol-mediated inhibition of transcription. Cell, 42, 203-
212.
PAPAGEORGE, A.G., DE FEO-JONES, D., ROBINSON, P., TEMEMLES,
G. & SCOLNICK, E.M. (1984). Saccharomyces cerevisiae syn-
thesises proteins related to the p21 gene product of ras genes
found in mammals. Mol. Cell. Biol., 4, 23-29.
QNINONES, S., SAUS, J., OTANI, Y., HARRIS, E.D. & KURKINEN, M.
(1989). Transcriptional regulation of human stromelysin. J. Biol.
Chem., 264, 8339-8344.
REDDY, E.B., REYNOLDS, R.K., SANTOS, E. & BARBACID, M. (1982).
A point mutation is responsible for the acquisition of tranform-
ing properties by the T24 human bladder carcinoma oncogene.
Nature, 300, 149-152.
REYMOND, C.D., GOMER, R.H., MEHDY, M.C. & FIRTEL, R.A.
(1984). Developmental regulation of a Dictyostelium gene
encoding a protein homologous to mammalian RAS protein.
Cell, 39, 141-148.
RUBIN, G.M. (1991). Signal transduction and the fate of the R7
photoreceptor in Drosophila. Trends Genet., 7, 372-376.
RYAN, W.A., FRANZA, B.R. & GILMAN, M.Z. (1989). 2 distinct cel-
lular phosphoproteins bind to the c-fos serum response element.
EMBO J., 8, 1785-1792.
SALZBERG, A., COHEN, N., HALACHMI, N., KIMCHIE, Z. & LEV, Z.
(1993). The Drosophila-Ras2 and Rop gene pair - a dual
homology with a yeast Ras-like gene and a suppressor of its
loss-of-function phenotype. Development, 117, 1309-1319.
SANTORO, C., MERMOD, N., ANDREWS, P.C. & TJIAN, R. (1988).
Cloning of cDNAs encoding human CCAAT-box binding pro-
teins: a family of transcription and replication factors. Nature,
334, 218-224.
SCHEJTER, E.D. & SHILO, B.-Z. (1985). Characterization of functional
domains of p21 ras by use of chimeric genes. EMBO J., 4,
407-412.
SCHNEIDER, I. (1972). Cell lines derived from late embryonic stages
of Drosophila melanogaster. J. Embryol. Exp. Morphol., 27,
353-365.
SEGAL, D. & SHILO, B.-Z. (1986). Tissue localization of Drosophila
melanogaster ras transcription during development. Mol. Cell.
Biol., 6, 2241-2248.
SHILO, B.-Z. (1987). Proto-oncogenes in Drosophila melanogaster.
Trends Genet., 3, 69-72.
SKAFAR, D.F. & NOTIDES, A.C. (1985). Modulation of the estrogen
receptor's affinity for DNA by estradiol. J. Biol. Chem., 260,
12208-12213.
SLEIGH, M.J. (1986). A nonchromatographic assay for expression of
the chloramphenicol acetyltransferase gene in eukaryotic cells.
Anal. Biochem., 156, 251-256.
SPANDIDOS, D.A. (1987). The consequences of quantitative and
qualitative changes of Harvey-ras gene expression in the process
of carcinogenesis. Anticancer Res., 7, 991-996.
SPANDIDOS, D.A. & RIGGIO, M. (1986). Promoter and enhancer-like
activity at the 5'-end of normal and T24 Ha-Rasl genes. FEBS
Lett., 203, 169-174.
STRUHL, K. (1987). Promoters, activator proteins, and the mech-
anism of trnascriptional initiation in yeast. Cell, 49, 295-297.
SWAROOP, A., SUN, J.-W., PACO-LARSON, M.L. & GAREN, A. (1986).
Molecular-organization and expression of the genetic-locus glued
in Drosophila melanogaster. Mol. Cell. Biol., 6, 833-841.
TABIN, C.J., BRADLEY, S.M., BARGMANN, C.I., WEINBERG, R.A.,
PAPAGEORGE, A.G., SCOLNICK, E.M., DHAR, R., LOWY, D.R. &
CHANG, E.H. (1982). Mechanism of activation of a human
oncogene. Nature, 300, 143-149.
TAMURA, T. & KATSUHIKO, M. (1991). Role of GC-rich motif in
transcription regulation of the adenovirus type 2 IVa2 promoter
which lacks typical TATA-box element. FEBS, 282, 87-90.
TAKAHIRO, N., YOSHIO, U. & SHUNSUKE, I. (1990). Transcriptional
control of the human Harvey ras proto-oncogene: role of mul-
tiple elements in the promoter region. Gene, 94, 249-253.
TANAKA, T., SLAMON, D.J., BATTIFORA, H. & CLINE, M.J. (1986).
Expression of p21 RAS oncoproteins in human cancers. Cancer
Res., 46, 1465-1470.
TAPAROWSKY, E., SUARD, Y., FASANO, O., SHIMIZU, K., GOLD-
FARB, M. & WIGLER, M. (1982). Activation of the T24 bladder
carcinoma transforming gene is linked to a single amino acid
change. Nature, 300, 762-765.
THEILLET, C., BRUNET, M., CALLAHAN, R., ESCOT, C., GEST, J.,
HUTZELL, P., LIDEREAU, R. & SCHLOM, J. (1986). Loss of a
c-Ha-rasl allele and aggressive human primary breast car-
cinomas. Cancer Res., 46, 4776-4781.
WADSWORTH, S.C., VINCENT, W.S. & BILODEAN-WENTWORTH, D.
(1985). A Drosophila genomic sequence with homology to human
epidermal growth factor receptor. Nature, 314, 178-180.
WILLIAMS, T.J. & FRIED, M. (1986). The MES-1 murine enhancer
element is closely associated with the heterogeneous 5' ends of 2
divergent transcription units. Mol. Cell. Biol., 6, 4558-4569.
XIAO, J.H., DAVIDSON, I., ROSALES, R., FERRANDON, D., VIG-
NERON, M., MACCHI, M. RUFFENACH, F. & CHAMBON, P.
(1987). One cell-specific and three ubiquitous nuclear proteins
bind in vitro to overlapping motifs in the domain BI of the SV40
enhancer. EMBO J., 6, 3005-3013.
YAMAGUCHI, M., HIROSE, F., NISHIDA, Y. & MATSUKAGE, A.
(1991). Repression of the Drosophila proliferating - cell nuclear
antigen gene promoter by zerknullt protein. Mol. Cell. Biol., 11,
4909-4917.
YU, C.Y., MOTAMED, K., CHEN, J., BAILEY, A.D. & SHEN, C.-K.J.
(1991). The CACC-box upstream of human embryonic epsilon
globin gene binds Spl and is a functional promoter element
in-vitro and in-vivo. J. Biol. Chem., 266, 8907-8915.